{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-164444","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2023-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.766766+00:00","generated_at":"2026-06-14T03:55:11.076086+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aeglea shareholders approve reverse stock split; equity incentive plan fails","bullets":["Alison Lawton and Hunter C. Smith elected as Class I directors with 26.8M and 33.8M shares for, respectively.","Ratification of PwC as auditor for FY 2023 approved with 46.9M shares for, 4.1M against.","Reverse stock split (1:10 to 1:25 ratio) approved by 44.1M shares for vs 5.5M against; board to select ratio.","Amendment and restatement of 2016 Equity Incentive Plan defeated: 19.1M for vs 19.3M against (excluding broker non-votes)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-164444","json":"https://secwatch.observer/filing/0001193125-23-164444.json","markdown":"https://secwatch.observer/filing/0001193125-23-164444.md","text":"https://secwatch.observer/filing/0001193125-23-164444.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523164444/0001193125-23-164444-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523164444/d492050d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T03:55:11.076086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8f6f14fb1e5c759402668e344c266a5a673a4c7d","claim":"Spyre Therapeutics, Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-06 meeting.","evidence_excerpt":"2. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: Shares For Shares Against Shares Abstaining 46,862,837 4,147,212 147,503","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523164444/0001193125-23-164444-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-06"}],"fact_type":"shareholder_vote"},{"claim_id":"b78c6f3d486ee2afda9d26c45e3fce4ffcd4aac8","claim":"Spyre Therapeutics, Inc. shareholders rejected Approval of an amendment and restatement of the Company’s 2016 Equity Incentive Plan at the 2023-06-06 meeting.","evidence_excerpt":"5. Approval of an amendment and restatement of the Company’s 2016 Equity Incentive Plan: Shares For Shares Against Shares Abstaining Broker Non-Votes 19,133,057 19,349,704 20,035 12,654,756","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523164444/0001193125-23-164444-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"failed"},{"label":"Meeting","value":"2023-06-06"}],"fact_type":"shareholder_vote"},{"claim_id":"cf20e1111232cf1f45549f8117b46943e5ccaf76","claim":"Spyre Therapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement for the 2023 Annual Meeting of Stockholders at the 2023-06-06 meeting.","evidence_excerpt":"3. Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement for the 2023 Annual Meeting of Stockholders: Shares For Shares Against Shares Abstaining Broker Non-Votes 23,331,453 11,712,005 3,459,338 12,654,756","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523164444/0001193125-23-164444-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-06"}],"fact_type":"shareholder_vote"},{"claim_id":"db7ee5da562bc26dac0fe7cbafde0626996c4298","claim":"Spyre Therapeutics, Inc. shareholders approved Approval of an amendment to the Company’s restated certificate of incorporation to effect a reverse stock split of the Company’s common stock at a ratio ranging from 1-for-10 shares up to a ratio of 1-for-25 shares, which ratio will be selected by the Company’s board of directors at the 2023-06-06 meeting.","evidence_excerpt":"4. Approval of an amendment to the Company’s restated certificate of incorporation to effect a reverse stock split of the Company’s common stock at a ratio ranging from 1-for-10 shares up to a ratio of 1-for-25 shares, which ratio will be selected by the Company’s board of directors: Shares For Shares Against Shares Abstaining 44,109,674 5,501,688 1,546,190","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523164444/0001193125-23-164444-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-06"}],"fact_type":"shareholder_vote"},{"claim_id":"f8cbdcb09ba48a15933d17ae71bfb82d7cfbfacb","claim":"Spyre Therapeutics, Inc. shareholders approved Election of two Class I directors, Alison Lawton and Hunter C. Smith, M.B.A., each to serve a three-year term at the 2023-06-06 meeting.","evidence_excerpt":"1. Election of two Class I directors, Alison Lawton and Hunter C. Smith, M.B.A., each to serve a three-year term, which will expire at the 2026 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until their earlier resignation or removal: Nominees Shares For Shares Withheld Shares Abstaining Broker Non-Votes Alison Lawton 26,794,716 11,708,080 — 12,654,756 Hunter C. Smith, M.B.A. 33,786,894 4,715,902 — 12,654,756","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000119312523164444/0001193125-23-164444-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-06"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}